Popular Joint Pain Supplement Linked to Faster Alzheimer's Decline

Alarming Discovery for Millions of Americans

A groundbreaking study published on June 9, 2026, in Nature Metabolism has revealed troubling news for the estimated 40 million Americans who regularly take glucosamine supplements for joint pain. People with Alzheimer's disease who took the common supplement glucosamine were 25% more likely to die within five years than those who didn't, with more than 40 million Americans taking it each year.

The research, conducted by University of Florida scientists, analyzed medical records from over 65,000 patients and found equally concerning results for those in earlier stages of cognitive decline. People in the early stage of dementia who were taking glucosamine were 25% more likely to progress to full Alzheimer's. The study was reported June 9 in the journal Nature Metabolism.

The analysis was based on anonymized medical records from the University of Florida Health system, including 24,000 patients with dementia and 41,000 with mild cognitive impairment, comparing people who took glucosamine with those who didn't.

The Science Behind the Risk

Researchers discovered a specific biological mechanism that may explain why glucosamine appears harmful to aging brains. Mechanistically, glucosamine may exacerbate Alzheimer's pathology by enhancing protein glycosylation, a metabolic process found to be overactive in Alzheimer's brains and linked to worsened memory deficits in mouse models.

Using advanced spatial biomolecule technology, senior author Dr. Ramon Sun discovered that the Alzheimer's brain suffers from an overactive protein sugar-tagging pathway. While healthy cells need precision sugar tags to fold proteins properly, the diseased brain adds too many sugar structures, gumming up cellular machinery.

Laboratory experiments with mice confirmed these findings. Glucosamine directly accelerated protein sugar-tagging, severely degrading the animals' social recognition memory. Chemically blocking this tagging process completely reversed the cognitive deficits.

A Tale of Two Populations

The study reveals a crucial distinction between healthy adults and those already experiencing cognitive problems. Earlier studies have linked glucosamine supplements to a lower dementia risk in cognitively healthy adults. Our findings do not contradict those reports but qualify them. While glucosamine appears safe and potentially protective for a healthy brain, it may be harmful for a brain that is already experiencing cognitive decline.

Taking glucosamine was associated with a 25% increase in mortality risk among ADRD patients. For the MCI group, there was no such impact, suggesting the impact of glucosamine may be greater in patients with established dementia. Researcher Matt Gentry noted, "While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention."

Implications for Future Treatment

The researchers suggest that "altered metabolism is a significant contributor to Alzheimer's progression and, in addition, addressing the metabolic defect could be an important complement to approaches focused on Alzheimer's plaques and tangles." This discovery opens new avenues for therapeutic intervention beyond traditional approaches.

One way to test whether glucosamine directly causes cognitive decline would be a clinical trial on patients who took glucosamine and then discontinued it. About 8% of dementia patients in the database fall into that category. Researchers hope to follow them for several years to see whether stopping the supplement slows their cognitive decline.

The findings suggest that millions of older adults taking glucosamine for joint health may need to reconsider their supplement regimen, particularly if they're experiencing any signs of memory problems. As researchers continue investigating this metabolic pathway, the discovery could reshape both supplement recommendations and Alzheimer's treatment strategies.